Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act

This bill mandates Medicare coverage for FDA-approved multi-cancer early detection (MCED) screening tests beginning in 2028. This is a direct market expansion for diagnostic companies, as Medicare is a primary payer for senior healthcare services. The coverage is limited to individuals under a certain age (age 68 in 2028, increasing annually) and one test every 11 months, establishing a recurring revenue model. The bill's introduction and referral to the Committee on Finance, coupled with 68 cosponsors, including the lead Republican on the Senate Finance Committee (Sen. Crapo), signals strong legislative momentum and a high likelihood of enactment. The money trail flows directly to diagnostic test developers and clinical laboratories. Once FDA-approved, these companies will receive reimbursement from Medicare for each MCED test performed. The Centers for Medicare & Medicaid Services (CMS) will determine appropriate coverage, but the bill establishes the framework for this reimbursement. The total addressable market for MCED tests expands significantly with Medicare coverage, potentially reaching billions of dollars annually as the eligible population grows and testing becomes routine. Companies like Illumina ($ILMN) through its GRAIL subsidiary, Quest Diagnostics ($DGX), LabCorp ($LH), Thermo Fisher Scientific ($TMO), and PerkinElmer ($PKI) are positioned to capture this new revenue stream. Exact Sciences ($EXAS) with its Cologuard test has a precedent in Medicare coverage for cancer screening, and this bill expands that concept to multi-cancer detection. Historically, Medicare coverage for new diagnostic technologies has led to substantial market growth for the companies involved. For example, when CMS finalized coverage for Cologuard, Exact Sciences' ($EXAS) stock surged. While specific historical data for multi-cancer early detection is limited due to its nascent stage, the precedent of Medicare coverage for other cancer screening tests (e.g., colonoscopies, mammograms, and specific genetic tests) demonstrates a clear path to market expansion. The passage of the Medicare and Medicaid Improvement Act of 2000, which expanded coverage for certain preventative services, led to sustained growth in the diagnostic sector. This bill provides a similar, direct catalyst. Specific winners include Illumina ($ILMN) due to its GRAIL subsidiary's Galleri test, which is a leading MCED platform. Quest Diagnostics ($DGX) and LabCorp ($LH) are major clinical laboratory networks that will perform these tests, benefiting from increased volume. Thermo Fisher Scientific ($TMO) and PerkinElmer ($PKI) supply the instrumentation and reagents for advanced diagnostic testing. Guardant Health ($GH) and Natera ($NTRA) are also developing liquid biopsy multi-cancer detection tests and stand to gain. Companies like Castle Biosciences ($CSTL) which focuses on diagnostic tests for skin cancer, could see an indirect benefit from increased awareness and diagnostic infrastructure. The next step is for the bill to be considered by the Senate Finance Committee. Given the strong bipartisan cosponsorship, including the committee's ranking member, the bill is likely to advance through committee. Following committee approval, it would proceed to a full Senate vote. If passed by the Senate, it would then move to the House of Representatives for consideration. The earliest coverage begins in 2028, providing a clear timeline for companies to prepare for market entry and reimbursement.